Abstract
Great advances have been made in the treatment of Tay–Sachs disease, one of a group of inherited diseases in which the degradation of sphingolipids is impaired. In the animal model, application of compound 1 was successful in inhibiting the biosynthesis of nondegradable enzyme substrates and in this way reducing the extent of the disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Angewandte Chemie International Edition in English
Paper Title
Journal
Date
